NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
09 mai 2024 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
08 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA
07 mai 2024 10h00 HE
|
Dipharma Francis S.r.l
Dipharma Inc. has been inspected by the US FDA and has received the EIR, satisfactorily closing the inspection process.
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
06 mai 2024 06h05 HE
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
02 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
01 mai 2024 16h30 HE
|
Block & Leviton LLP
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abeona Therapeutics, Inc. (NASDAQ: ABEO) for potential securities law violations. Investors who have lost money in their...
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
25 avr. 2024 08h00 HE
|
Compass Therapeutics
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study...
SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
23 avr. 2024 10h29 HE
|
Block & Leviton LLP
BOSTON, April 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abeona Therapeutics, Inc. (NASDAQ: ABEO) for potential securities law violations. Investors who have lost money in...
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
23 avr. 2024 08h15 HE
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...